Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) was the target of a significant decline in short interest in February. As of February 27th, there was short interest totaling 2,779 shares, a decline of 35.3% from the February 12th total of 4,293 shares. Based on an average daily trading volume, of 18,863 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 18,863 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. DRW Securities LLC purchased a new position in Pulmatrix in the 4th quarter valued at $46,000. Dimensional Fund Advisors LP purchased a new stake in shares of Pulmatrix during the third quarter worth $52,000. Finally, SBI Securities Co. Ltd. raised its position in shares of Pulmatrix by 15.7% in the second quarter. SBI Securities Co. Ltd. now owns 60,565 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 8,208 shares during the last quarter. 11.84% of the stock is owned by institutional investors and hedge funds.

Pulmatrix Stock Down 2.3%

Shares of PULM stock traded down $0.05 on Friday, reaching $2.11. 10,821 shares of the company were exchanged, compared to its average volume of 52,620. Pulmatrix has a 1 year low of $1.63 and a 1 year high of $9.37. The business has a 50-day moving average price of $2.49 and a 200 day moving average price of $3.75.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulmatrix in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).